Novacap completes the acquisition of PCI Synthesis and expands its pharmaceutical offering in the U.S.

Thursday 28 of June, Novacap has completed the acquisition of PCI Synthesis, a Pharmaceutical Development CDMO.

Based in Newburyport, MA PCI Sunthesis is the largest small molecule drug substance manufacturer in the New England area. PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules.

Read the press release

more about PCI Synthesis